Every Form 4 that Pulmonx Corporation (LUNG) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow LUNG and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full LUNG filings page.
Pulmonx Corp (LUNG) reported that President and CEO, and director, Glendon E. French III sold a total of 41,882 shares of common stock on September 1, 2026 at $2.26 per share in transactions described as sales to cover tax withholding obligations arising from the vesting of Restricted Stock Units granted on March 1, 2023 and December 1, 2025. A footnote also notes the acquisition of 1,656 shares under Pulmonx’s 2020 Employee Stock Purchase Plan on August 14, 2026, and French is reported as indirectly holding 918,198 shares of common stock through a family trust for which he and his spouse serve as trustees and beneficiaries. No Rule 10b5-1 trading plan is reported for these transactions.
Pulmonx Corp (LUNG) reported that Chief Science & Technology Officer Radhakrishnan Srikanth sold an aggregate of 14,245 shares of common stock on September 1, 2026 at $2.26 per share. The filing states each sale was made to cover tax withholding obligations arising from vesting of Restricted Stock Units granted between March 2023 and March 2026. No Rule 10b5-1 trading plan is indicated, and post-transaction share holdings are not reported in this filing.
Pulmonx Corp (LUNG) reported that its General Counsel, David Aaron Lehman, sold an aggregate 14,334 shares of Common Stock on September 1, 2026 at $2.26 per share in four open-market or private transactions. Footnotes state that each sale covered tax withholding obligations arising from the vesting of Restricted Stock Units granted in 2023, 2024, 2025, and 2026, and no Rule 10b5-1 trading plan is reported.
Pulmonx Corp (LUNG) reported that Chief Commercial Officer Rose Geoffrey Beran sold a total of 7,879 shares of common stock on September 1, 2026, in four open-market transactions at $2.26 per share. Footnotes state each sale was made to cover tax withholding obligations arising from the vesting of Restricted Stock Units granted in 2023, 2024, 2025, and 2026. No Rule 10b5-1 trading plan is reported.
Burns Thomas William reported acquisition or exercise transactions in this Form 4 filing.
Pulmonx Corp director Thomas William Burns received an equity grant in the form of restricted stock units. The award covers 40,000 shares of Pulmonx common stock at a stated price of $0.0000 per share, reflecting a compensation grant rather than a market purchase.
According to the terms, the restricted stock units vest on the earlier of the one-year anniversary of the June 5, 2026 grant date (or the next business day) or the date of the Annual Meeting of the Stockholders for the year after the grant. Following this grant, Burns directly holds 113,399 shares of Pulmonx common stock.
Ferrari Richard reported acquisition or exercise transactions in this Form 4 filing.
Pulmonx Corp director Richard Ferrari reported an equity award. He received 40,000 shares of common stock through a grant of Restricted Stock Units at a stated price of $0.00 per share. These RSUs vest on the earlier of the one-year anniversary of the June 5, 2026 grant date or the next annual stockholders’ meeting. Following this award, Ferrari directly holds 127,024 Pulmonx shares.
Florin Daniel P reported acquisition or exercise transactions in this Form 4 filing.
Pulmonx Corp director Florin Daniel P reported an award of 40,000 shares of Common Stock in the form of restricted stock units. These RSUs were granted at no cash cost and increase his direct holdings to 133,910 shares following the transaction.
The RSU grant vests on the earlier of the one-year anniversary of the June 5, 2026 grant date, or the date of the company’s next annual stockholder meeting for the subsequent year, subject to the business day convention described.
Melenikiotou Georgia reported acquisition or exercise transactions in this Form 4 filing.
Pulmonx Corp director Georgia Melenikiotou reported an equity compensation grant. She was awarded 40,000 shares of common stock as a grant of Restricted Stock Units on June 5, 2026, with no cash paid per share. Following this award, her direct holdings total 139,714 common shares.
The RSUs vest on the earlier of the one-year anniversary of the June 5, 2026 grant date, adjusted to the next business day if needed, or the date of the Annual Meeting of the Stockholders for the year after the grant.
Sullivan Tiffany reported acquisition or exercise transactions in this Form 4 filing.
Pulmonx Corp director Tiffany Sullivan received an equity grant in the form of restricted stock units. The Form 4 reports an award of 40,000 shares of common stock at a price of $0.0000 per share, reflecting a compensation-related grant rather than an open-market purchase.
The RSU Grant vests on the earlier of the one-year anniversary of the grant date of June 5, 2026 (or the next business day) or the date of the Annual Meeting of the Stockholders for the year after the grant. Following this grant, Sullivan directly holds 115,199 common shares.
Mead Dana G Jr. reported acquisition or exercise transactions in this Form 4 filing.
Pulmonx Corp director Dana G. Mead Jr. received a grant of 40,000 Restricted Stock Units payable in common stock. This is a stock-based compensation award, not an open-market purchase.
The RSUs vest on the earlier of June 5, 2026 or the company’s next annual stockholder meeting. After this grant, Mead holds 139,714 Pulmonx common shares directly and 4,076 shares indirectly through The Mead Family Trust.
Pulmonx Corp Chief Science & Techn. Officer Radhakrishnan Srikanth reported routine share sales tied to tax withholding. On June 1, 2026, he sold a total of 14,497 shares of Pulmonx common stock in four open-market transactions at $1.54 per share. According to the footnotes, each sale was made solely to cover tax withholding obligations arising from the vesting of Restricted Stock Units granted on March 1, 2023, March 1, 2024, March 3, 2025, and March 2, 2026.
Pulmonx Corp General Counsel David Aaron Lehman reported the sale of a total of 14,594 shares of Pulmonx common stock on June 1, 2026 at a price of $1.54 per share, executed in four separate transactions. According to the footnotes, all of these shares were sold solely to cover tax withholding obligations arising from the vesting of Restricted Stock Units granted on March 1, 2023, March 1, 2024, March 3, 2025, and March 2, 2026, making the activity compensation- and tax-related rather than a discretionary reduction of his investment position.
Pulmonx Corp’s Chief Commercial Officer Geoffrey Beran Rose reported selling a total of 8,023 shares of common stock on June 1, 2026 in four transactions at $1.5400 per share. Footnotes state these sales were made to cover tax withholding obligations related to vesting Restricted Stock Units granted from 2023 through 2026. After these transactions, he directly holds 457,711 Pulmonx common shares.
Pulmonx Corp President and CEO Glendon E. French III reported tax-related share sales. On June 1–2, 2026, he sold a total of 56,149 shares of Common Stock at prices around $1.54–$1.57 per share. A footnote explains these shares were sold to cover tax withholding obligations tied to vesting of Restricted Stock Units granted on March 1, 2023, making them compensation-related rather than discretionary trades. After the transactions, he held 1,178,162 shares directly, and a family trust held an additional 918,198 shares indirectly.
Pulmonx Corp’s Chief Science & Technology Officer, Radhakrishnan Srikanth, reported routine equity-related transactions in company common stock. On March 2, 2026, he sold a total of 10,483 shares at $1.43 per share solely to cover tax withholding obligations tied to the vesting of previously granted Restricted Stock Units (RSUs) from 2022–2025.
On the same date, he received a grant of 175,000 RSUs, payable solely in Pulmonx common stock, which will vest in equal quarterly installments over a four-year period starting on March 2, 2026. Following these transactions, his directly held common stock position is reported at 345,736 shares.
Pulmonx Corp President and CEO Glendon E. French III reported open-market sales of 67,813 shares of common stock. The sales occurred on March 2, 2026 at $1.43 per share in three transactions. Footnotes state the shares were sold to cover tax withholding obligations tied to vesting of restricted stock units granted in 2022 and 2023. After these sales, he directly held 1,409,511 shares, with an additional 742,998 shares held indirectly by a family trust.
Pulmonx Corp reported insider transactions by its Chief Commercial Officer, Geoffrey Beran. On March 2, 2026, he sold a total of 7,732 shares of common stock at $1.43 per share in open-market sales to cover tax withholding obligations tied to vesting restricted stock units granted in 2022, 2023, 2024, and 2025.
On the same date, he received a grant of 100,000 restricted stock units, payable solely in Pulmonx common stock, which vest in equal quarterly installments over four years from March 2, 2026. Following these transactions, his direct holdings increased to 465,734 shares of common stock.
Pulmonx Corp’s general counsel, David Aaron Lehman, reported multiple insider transactions in Pulmonx common stock. On March 2, 2026, he sold a total of 12,237 shares in open‑market transactions at $1.43 per share. Footnotes state these sales were made to cover tax withholding obligations tied to the vesting of restricted stock units (RSUs) granted between March 1, 2022 and March 3, 2025, indicating they were not discretionary portfolio sales. On the same date, he received a grant of 150,000 RSUs payable solely in common stock, vesting in equal quarterly installments over four years from March 2, 2026. Following these transactions, his directly held Pulmonx shares increased to 390,755.
Pulmonx Corp reported new equity awards to its Chief Operating Officer and Chief Financial Officer on December 1, 2025. The executive received 1,200,000 Restricted Stock Units that are payable in common stock. According to the terms, 25% of these units vest one year after the grant date, with the remaining balance vesting in equal quarterly installments over the following three years.
The executive also received 400,000 Performance Stock Units, each tied to one share of common stock. These units vest only if two conditions are met: the company’s stock reaches a specified price per share and time-based milestones are satisfied, with 33% vesting one year after the grant date and the rest in eight equal quarterly installments through December 1, 2028. Both awards are shown at a price of $0, reflecting that they are equity incentives rather than open-market purchases.